Bio-Techne (TECH) said Thursday it expanded an agreement with Oxford Nanopore Technologies, allowing it to develop a portfolio of genetic products on Oxford platforms.
The company said it was granted expanded commercial rights to develop a portfolio of sequencing kits to screen and diagnose heritable genetic disorders.
Bio-Techne said its collaboration with Oxford is extended through 2032 under the expanded agreement, which also establishes a framework to define and propose future portfolios.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.